Vesting under the Restricted Share Unit Plan (the“RSU Plan”) and PDMR purchases ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

UEFA president Aleksander Ceferin has rejected FIFA's proposal to expand the 2030 men’s World Cup in Morocco, Spain, and ...

FIFA is expected to announce on Thursday that the U.S. and the U.K. will be selected as hosts for the expanded Women’s World ...

Site analysis reports, flood studies and seismic safety studies - as well as technical feasibility studies by potential ...

As stated, the approval of verification prototypes of vehicles is underway, which is one of the steps announced within Croatia’s National Recovery and Resilience Plan. Each prototype tests out ...

SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company ...

The table below provides a high-level summary of the patient demographic and safety data. Simufilam continued to demonstrate an overall favorable safety profile.

SAVA has a new potential indication for simufilam ... The Company also outlined its plan to discontinue the Phase 3 REFOCUS-ALZ study and Open Label Extension study and to analyze the complete ...